Secura Drug Patent Portfolio
Secura owns 2 orange book drugs protected by 11 US patents Given below is the list of Secura's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12213983 | Treatment of cancers using PI3 kinase isoform modulators | 26 Apr, 2035 | Active |
| USRE46621 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | 17 May, 2032 | Active |
| US11312718 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | 10 Jan, 2032 | Active |
| US9840505 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof | 10 Jan, 2032 | Active |
| US8193182 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | 13 Feb, 2030 | Active |
| US9216982 | Certain chemical entities, compositions and methods | 05 Jan, 2029 | Active |
| US8883842 | Use of HDAC inhibitors for the treatment of myeloma | 13 Jun, 2028 | Active |
| US7989494 | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | 17 Jan, 2028 | Active |
| US6833384 | Deacetylase inhibitors | 30 Sep, 2021 | Expired |
| US6552065 | Deacetylase inhibitors | 31 Aug, 2021 | Expired |
| US7067551 | Deacetylase inhibitors | 31 Aug, 2021 | Expired |
Latest Legal Activities on Secura's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Secura.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 22 Dec, 2023 | US8193182 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Dec, 2023 | US8193182 |
| Requirement for information sent under 37 CFR 1.750 | 18 Aug, 2023 | US8193182 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Jun, 2023 | US9216982 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 25 Jan, 2023 | US7989494 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 11 May, 2022 | US8883842 |
|
Recordation of Patent Grant Mailed
Critical
| 26 Apr, 2022 | US11312718 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 Apr, 2022 | US11312718 |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Apr, 2022 | US8193182 |
|
Email Notification
Critical
| 07 Apr, 2022 | US11312718 |
|
Issue Notification Mailed
Critical
| 06 Apr, 2022 | US11312718 |
| Mail Miscellaneous Communication to Applicant | 04 Apr, 2022 | US11312718 |
|
Application Is Considered Ready for Issue
Critical
| 29 Mar, 2022 | US11312718 |
| Dispatch to FDC | 29 Mar, 2022 | US11312718 |
| Miscellaneous Communication to Applicant - No Action Count | 25 Mar, 2022 | US11312718 |
Secura Drug Patents' Oppositions Filed in EPO
Secura drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 17, 2016, by Generics [Uk] Limited. This opposition was filed on patent number EP06789025A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP06789025A | Mar, 2016 | Generics [UK] Limited | Opposition rejected |
Secura's Family Patents
Secura Drug List
Given below is the complete list of Secura's drugs and the patents protecting them.
1. Copiktra
Copiktra is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12213983 | Treatment of cancers using PI3 kinase isoform modulators |
26 Apr, 2035
(9 years from now)
| Active |
| USRE46621 | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
17 May, 2032
(7 years from now)
| Active |
| US11312718 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
10 Jan, 2032
(6 years from now)
| Active |
| US9840505 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
10 Jan, 2032
(6 years from now)
| Active |
| US8193182 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
13 Feb, 2030
(4 years from now)
| Active |
| US9216982 | Certain chemical entities, compositions and methods |
05 Jan, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Copiktra's drug page
2. Farydak
Farydak is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8883842 | Use of HDAC inhibitors for the treatment of myeloma |
13 Jun, 2028
(3 years from now)
| Active |
| US7989494 | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
17 Jan, 2028
(2 years from now)
| Active |
| US6833384 | Deacetylase inhibitors |
30 Sep, 2021
(3 years ago)
| Expired |
| US6552065 | Deacetylase inhibitors |
31 Aug, 2021
(3 years ago)
| Expired |
| US7067551 | Deacetylase inhibitors |
31 Aug, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Farydak's drug page